Matches in Wikidata for { <http://www.wikidata.org/entity/Q96579683> ?p ?o ?g. }
Showing items 1 to 47 of
47
with 100 items per page.
- Q96579683 description "article scientifique publié en 2020" @default.
- Q96579683 description "artículu científicu espublizáu en mayu de 2020" @default.
- Q96579683 description "im Mai 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q96579683 description "scientific article published on 26 May 2020" @default.
- Q96579683 description "wetenschappelijk artikel" @default.
- Q96579683 description "наукова стаття, опублікована 26 травня 2020" @default.
- Q96579683 name "Long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer" @default.
- Q96579683 name "Long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer" @default.
- Q96579683 type Item @default.
- Q96579683 label "Long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer" @default.
- Q96579683 label "Long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer" @default.
- Q96579683 prefLabel "Long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer" @default.
- Q96579683 prefLabel "Long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer" @default.
- Q96579683 P1433 Q96579683-C6644593-8741-42A8-8EBE-056D81E4A7D9 @default.
- Q96579683 P1476 Q96579683-0DC36BF3-BF35-49A9-850D-294DB94A6D55 @default.
- Q96579683 P2093 Q96579683-46ED1FB9-6E0B-4F4F-9A36-0FD43085CC55 @default.
- Q96579683 P2093 Q96579683-5CFC1405-580F-4F9C-899B-6778CD0841EE @default.
- Q96579683 P2093 Q96579683-D8FF8CE3-CBED-4941-956A-A778732A3797 @default.
- Q96579683 P2093 Q96579683-FE52D668-7594-4788-807A-CFE866BD0E3A @default.
- Q96579683 P304 Q96579683-75C8C39A-04E1-4B65-8F8C-14053D9854A5 @default.
- Q96579683 P31 Q96579683-C0337E83-1553-427E-B058-CF817383BD25 @default.
- Q96579683 P356 Q96579683-18153293-A57B-4354-BA3A-D9B87CF6A274 @default.
- Q96579683 P478 Q96579683-1A4F118B-A693-47C3-826D-88B370B29F1E @default.
- Q96579683 P577 Q96579683-CDEE4C17-DD4C-45AD-A2BA-4D68ECD916C2 @default.
- Q96579683 P698 Q96579683-FD8D01C4-6C0A-44FD-BA39-FC21A88F40FB @default.
- Q96579683 P921 Q96579683-65D3D080-DF93-46C4-9FA6-16D925D1EC18 @default.
- Q96579683 P921 Q96579683-B01A79C2-7442-4B4C-BE3B-1B0CC74D8391 @default.
- Q96579683 P921 Q96579683-EFB349D9-BD29-4125-867A-4DBE0B355EA1 @default.
- Q96579683 P932 Q96579683-ADDF1BAD-D79A-4F46-A1E5-D290123FCD0A @default.
- Q96579683 P356 J.GORE.2020.100581 @default.
- Q96579683 P698 32551353 @default.
- Q96579683 P1433 Q27726321 @default.
- Q96579683 P1476 "Long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer" @default.
- Q96579683 P2093 "Daniel S Kapp" @default.
- Q96579683 P2093 "David S Lakomy" @default.
- Q96579683 P2093 "John K Chan" @default.
- Q96579683 P2093 "Yassmina McDonald" @default.
- Q96579683 P304 "100581" @default.
- Q96579683 P31 Q13442814 @default.
- Q96579683 P356 "10.1016/J.GORE.2020.100581" @default.
- Q96579683 P478 "33" @default.
- Q96579683 P577 "2020-05-26T00:00:00Z" @default.
- Q96579683 P698 "32551353" @default.
- Q96579683 P921 Q13896859 @default.
- Q96579683 P921 Q1427096 @default.
- Q96579683 P921 Q944777 @default.
- Q96579683 P932 "7292902" @default.